Established in 1887 by William McLaren Bristol and John Ripley Myers, Bristol-Myers Squibb Company is a pharmaceutical company. Headquartered in New York, the company specializes in the development, manufacturing, licensing, and distribution of a wide range of pharmaceutical products.
The company’s pipeline of drugs includes novel treatments for oncology, immunoscience as well as cardiovascular and fibrotic illnesses. It’s lead products is Opdivo, a novel treatment for anti-cancer indications. It also sales Eliquis an oral inhibitor for stroke prevention as well as Orencia for patients with prostate-specific antigen.
Bristol-Myers Squibb Company has grown to become a juggernaut in the pharmaceutical space through acquisitions. Its biggest acquisition to date is that of Celgene in a deal valued at $74 billion. The acquisition should strengthen the company’s pipeline for cancer drugs and shrug of the effects of declining sales for lead product Opdivo.
Bristol-Myers Squibb Company has its stock listed on the New York Stock Exchange and is a component of the S&P 500 and S&P 100.
Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.